Current Report Filing (8-k)
May 10 2023 - 9:33AM
Edgar (US Regulatory)
0001704287
false
0001704287
2023-05-10
2023-05-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
May 10, 2023
Bluejay Diagnostics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| delaware |
|
001-41031 |
|
47-3552922 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission File No.) |
|
(I.R.S. Employer
Identification No.) |
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
(Address of principal executive offices and zip code)
(844) 327-7078
(Registrant’s telephone number, including area
code)
(Former name or former address, if changed from last
report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)). |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading Symbol (s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
BJDX |
|
The NASDAQ Stock Market LLC |
Item 2.02 Results of Operations and Financial Condition.
On May
10, 2023, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter
end March 31, 2023 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated
by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of
the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Bluejay Diagnostics Inc. |
| |
|
| |
By: |
/s/ Kenneth Fisher |
| |
|
Kenneth Fisher |
| |
|
Chief Financial Officer |
Dated: May 10, 2023
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Jan 2024 to Jan 2025
